Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Till Milde

Showing results (11-20 of 161) with videos related to

Pageof 17
Sort By:
Annals of Hematology|July 15, 2025
Successful treatment with mesenchymal stromal cells-Frankfurt am Main in a pediatric patient with steroid-refractory and ruxolitinib-refractory acute gastrointestinal graft-versus-host diseaseJana Ernst, Steffen Reinsch, Hans-Joachim Mentzel, et al.
Cancer Reports (Hoboken, N.J.)|May 5, 2026
Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma CellsNatalie Aderhold, Lisa Immesberger, Sabine Becker, et al.
Journal of Cancer Research and Clinical Oncology|April 4, 2025
Significance of busulfan administration route including therapeutic drug monitoring in the conditioning regimen of pediatric patients prior to hematopoietic stem cell transplantationStephanie Hämmerle, Jana Ernst, Regula Steiner, et al.
Anti-Cancer Drugs|September 4, 2008
HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cellsDennis Wegener, Hedwig E Deubzer, Ina Oehme, et al.
European Journal of Haematology|January 5, 2026
Efficacy and Safety of Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric PatientsDinah Walther, Jana Ernst, Carola Wollenhaupt, et al.
Cancer Chemotherapy and Pharmacology|May 29, 2026
Autophagy impairs the sensitivity of Ewing sarcoma cells to PARP inhibitorsJulia Clausen, Daniela Kocher, Hauke M Schadwinkel, et al.
Neuro-Oncology|June 16, 2021
Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomasTill Milde, Fausto J Rodriguez, Jill S Barnholtz-Sloan, et al.
Pediatric Blood & Cancer|December 13, 2017
Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenibCornelis M van Tilburg, Florian Selt, Felix Sahm, et al.
Cancers|December 10, 2021
SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk MedulloblastomaMartin Mynarek, Till Milde, Laetitia Padovani, et al.
Journal of Neuro-Oncology|January 7, 2024
Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cellsSimon Zeuner, Johanna Vollmer, Romain Sigaud, et al.
Pageof 17

Showing results (11-20 of 161) with videos related to

Sort By:
Pageof 17
Annals of Hematology|July 15, 2025
Successful treatment with mesenchymal stromal cells-Frankfurt am Main in a pediatric patient with steroid-refractory and ruxolitinib-refractory acute gastrointestinal graft-versus-host diseaseJana Ernst, Steffen Reinsch, Hans-Joachim Mentzel, et al.
Cancer Reports (Hoboken, N.J.)|May 5, 2026
Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma CellsNatalie Aderhold, Lisa Immesberger, Sabine Becker, et al.
Journal of Cancer Research and Clinical Oncology|April 4, 2025
Significance of busulfan administration route including therapeutic drug monitoring in the conditioning regimen of pediatric patients prior to hematopoietic stem cell transplantationStephanie Hämmerle, Jana Ernst, Regula Steiner, et al.
Anti-Cancer Drugs|September 4, 2008
HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cellsDennis Wegener, Hedwig E Deubzer, Ina Oehme, et al.
European Journal of Haematology|January 5, 2026
Efficacy and Safety of Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric PatientsDinah Walther, Jana Ernst, Carola Wollenhaupt, et al.
Cancer Chemotherapy and Pharmacology|May 29, 2026
Autophagy impairs the sensitivity of Ewing sarcoma cells to PARP inhibitorsJulia Clausen, Daniela Kocher, Hauke M Schadwinkel, et al.
Neuro-Oncology|June 16, 2021
Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomasTill Milde, Fausto J Rodriguez, Jill S Barnholtz-Sloan, et al.
Pediatric Blood & Cancer|December 13, 2017
Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenibCornelis M van Tilburg, Florian Selt, Felix Sahm, et al.
Cancers|December 10, 2021
SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk MedulloblastomaMartin Mynarek, Till Milde, Laetitia Padovani, et al.
Journal of Neuro-Oncology|January 7, 2024
Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cellsSimon Zeuner, Johanna Vollmer, Romain Sigaud, et al.
Pageof 17